Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A key hormone in the fetal liver has been found for the first time to play a critical role in determining iron endowment in the newborn baby. Up until now, widely held notions made in comparison to how the adult liver controls iron in the body have led to a common focus on how maternal iron status and function of the placenta determines a baby's iron status. A new study from the Lakhal-Littleton group reveals a more autonomous process takes place within the fetus than previously understood.

Samira's visual abstract for iron paper Blood June 2020

Historically, research into iron has focused on its role in the synthesis of haemoglobin, the substance in red blood cells that carries oxygen from your lungs throughout your body. However, in recent years evidence has been uncovered that iron plays an important role in many other physiological processes. For example, iron deficiency has been shown to impair cardiovascular function independently of haemoglobin levels in key Lakhal-Littleton lab papers in eLife and PNAS. In infancy, iron deficiency is associated with growth retardation and both motor skill and cognitive defects, because iron is required for the synthesis of myelin, an essential component of neurons, and also for rapid bone and muscle growth during childhood. While it is known that a liver-derived hormone called Hepcidin is responsible for regulating iron in the body, what is not well understood is the role it plays in the development of the unborn baby during pregnancy.

In the adult, it has been known for some time that hepcidin controls iron homeostasis by blocking the iron exporter ferroportin in the gut and spleen, which are sites of iron absorption and recycling respectively, thereby preventing iron from leaving these sites and being acquired into the bloodstream. Hepcidin is also present in the fetal liver, while ferroportin is found in abundance in the placenta, the organ where nutrients including iron are transferred from the mother to the fetus. Therefore, up until now, it has been widely accepted that the fetal liver controls iron availability to the fetus by operating in a similar manner to hepcidin in the adult liver; by blocking ferroportin in the placenta and thus preventing iron from being acquired into the mother’s circulation. This long-standing assumption heavily implies that fetal hepcidin is a negative regular of fetal iron levels.

A new paper from the Lakhal-Littleton lab has shown for the first time that fetal liver hepcidin does not control ferroportin in the placenta. Instead, the research reveals that fetal liver hepcidin acts cell-autonomously to block iron export out of fetal hepatocytes. This process enables the fetal liver to achieve rapid build-up of liver iron stores in the third trimester of gestation that is independent from both the iron status of the mother and from placental function. This key finding means that the fetal liver plays an active rather than passive role in determining iron endowment in the newborn. It can therefore be considered a positive regulator. 

According to lead researcher Associate Professor Samira Lakhal-Littleton: “The fundamental misunderstanding is that the levels of iron endowment in newborns are dependent on the transfer of maternal iron into the fetus across the placenta. The fetal liver was seen as a passive bystander in this process. As such, studies concerned with understanding the determinants of newborn iron endowment have focussed on maternal iron status and on placental function.”

Iron deficiency is very common amongst pregnant women because of the high demand for iron during the third trimester. The team’s results present important implications for the medical advice given to women during this stage of pregnancy. Prof Lakhal-Littleton said: “The decision as to whether to supplement these women with iron is based on their haemoglobin levels rather than on any measure relating to fetal iron status. The present study highlights the need to consider fetal iron levels in this process. This is not done currently because it is assumed that fetal iron status is entirely dependent on maternal iron status. Our study challenges that assumption.”

The team have also shown that this rapid accumulation of liver iron stores in the fetus supports the development of red blood cells, which at this stage occurs mainly in the fetal liver. Prof Lakhal-Littleton said: “It has been known for some time that fetal red blood cells develop in the fetal liver in late gestation. What was unclear, is how these developing red blood cells acquired the iron they need to make haemoglobin. What our study demonstrates is that iron stored in fetal liver cells acts as a supply of iron for developing red blood cells in the fetal liver.”

Liver iron endowment at birth is an important determinant of physical and neurological growth. This study ultimately shows that fetal liver hepcidin is essential for ensuring adequate iron endowment at birth.

“Up to now, clinicians have not been concerned with measuring fetal hepcidin. This can be done in cord blood. There is evidence that inflammatory conditions that occur during pregnancy affect maternal hepcidin levels, such as preeclampsia. What we need to understand is how fetal hepcidin is affected in these conditions, and whether changes in fetal hepcidin contribute to the developmental defects associated with such conditions.” (Prof Lakhal-Littleton).

The full paper, "Fetal liver hepcidin secures iron stores in utero" is available to read in "Blood".


Similar stories

Key cause of type 2 diabetes uncovered

Research led by Dr Elizabeth Haythorne and Professor Frances Ashcroft reveals high blood glucose reprograms the metabolism of pancreatic beta-cells in diabetes. They have discovered that glucose metabolites, rather than glucose itself, are key to the progression of type 2 diabetes. Glucose metabolites damage pancreatic beta-cell function, so they are unable to release enough of the hormone insulin. Reducing the rate at which glucose is metabolised, and these glucose metabolites build up, can prevent the effects of hyperglycaemia.

Winners of the DPAG Student Poster Day 2022 announced

"A Year of Progress" was held in the Sherrington Library on Wednesday 9 November 2022.

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

Updating the circuit maps of the sympathetic neural network

A new review from Professor Ana Domingos’ lab and colleagues offers a fresh modern viewpoint on sympathetic neurons and their relation to immune cells and obesity.

New Pfizer grant paves the way to a better understanding of how body fat is controlled

Professor Ana Domingos has been awarded a highly competitive independent research grant from Pfizer to discover ‘the role of Sympathetic-associated Perineurial barrier Cells in obesity’.